Alectinib in Elderly Patients — and Those With Other Illnesses

No. Age alone is not a reason to reduce the standard dose. Clinical trials of alectinib included older patients and found no systematic basis for an age-based adjustment. What your team assesses instead is your liver function, your heart rhythm, and the other medicines you take. If those are within an acceptable range, the standard dose applies regardless of how old you are.

Alectinib is processed by the liver, so this is the comorbidity your team will look at most carefully. For mild liver impairment, the standard dose is generally used alongside more frequent monitoring. For severe liver impairment the evidence base is limited, and your oncologist will weigh the risks carefully before deciding. Liver function tests are checked at regular intervals — typically more frequently in the early months of treatment — for all patients on alectinib.

A slow heart rate — bradycardia — is a recognised side effect of alectinib, even in patients with healthy hearts. If you already have a condition that affects your heart rhythm, or if you take medicines that slow the heart, your team will want to know before you start. Monitoring includes regular pulse checks, and your team may ask you to record your heart rate at home. Symptomatic bradycardia — dizziness, feeling faint, or breathlessness alongside a slow pulse — should be reported the same day.

For most degrees of kidney disease, the dose does not change. Alectinib leaves the body mainly through the digestive system rather than through the kidneys, so reduced kidney function has little effect on how the drug is cleared. This distinguishes alectinib from many other cancer medicines where renal impairment directly affects dosing. Your prescribing information and NCCN guidance both reflect that dose adjustment for renal impairment is generally not required.

Yes, interactions are possible and worth a careful review. Alectinib is broken down by a liver enzyme called CYP3A4. Medicines that strongly affect that enzyme — including some antibiotics, antifungals, and anticonvulsants — can raise or lower the level of alectinib in your blood. Some blood pressure medicines also warrant a check, particularly those that affect heart rate. Bring a complete list of everything you take, including over-the-counter tablets and supplements, to your first appointment so your pharmacist can review it.

Interstitial lung disease and pneumonitis are recognised but uncommon side effects of alectinib. If you already have a lung condition — such as chronic obstructive pulmonary disease or previous radiation to the chest — your team will establish your baseline breathing before treatment starts and watch for any new or worsening breathlessness. New breathlessness, a new persistent cough, or fever during alectinib should be reported the same day, as these can be early signs of a lung reaction that needs prompt assessment.

There is no direct interaction between alectinib and blood glucose that typically requires a dose change for either treatment. However, if alectinib causes significant muscle pain or fatigue — both common side effects — reduced activity can affect blood sugar control. Tell your diabetes team or oncologist if your glucose readings change noticeably after starting alectinib. A medicines review at the start of treatment is also sensible, since some antidiabetic agents interact via the same liver enzyme pathway that processes alectinib.

Ask a family member to watch for three things: a pulse that feels unusually slow or irregular, new or worsening breathlessness, and any yellowing of the skin or whites of the eyes. A slow pulse with dizziness or discomfort, and new breathlessness, are both recognised side effects of alectinib that need same-day reporting. Yellowing of the eyes or skin is a sign of possible liver involvement and also needs a same-day call. For most symptoms, call the oncology team first rather than going straight to an emergency department — they will direct you to the right level of care.